Abstract
The Italian Board on Urticaria has prepared a document focusing on the definition and classification of urticaria, taking into account the recent progress in identifying the causes, eliciting factors, and pathomechanisms of this disease. As urticaria has a profound impact on the quality of life, effective treatment is important. Therefore, specific treatment options for the management of urticaria are evaluated on the basis of the recent literature. Non-sedating H1 antihistamines are recommended as the first-line treatment as they have proven effective in several randomized double-blind controlled studies. Dosages higher than those recommended may be necessary in some cases. However, additional or alternative therapies may be required for different urticaria subtypes and in view of individual variations in the course of the disease and response to treatment. Immunosuppressive drugs such as corticosteroids are not recommended for long-term treatment due to unavoidable, severe adverse effects.
| Original language | English |
|---|---|
| Pages (from-to) | 297-311 |
| Number of pages | 15 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 144 |
| Issue number | 3 |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Adrenal cortex hormones
- Immunosuppressive agents
- Urticaria
ASJC Scopus subject areas
- Dermatology
Cite this
Italian position paper on urticaria. / Pigatto, P. D.; Marsili, C. B.; Ayala, F.; Depità, O.; Gelmetti, C.; Giannetti, A.; Girolomoni, G.; Vena, G. A.; Cassano, N.; Ayala, F.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 144, No. 3, 2009, p. 297-311.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Italian position paper on urticaria
AU - Pigatto, P. D.
AU - Marsili, C. B.
AU - Ayala, F.
AU - Depità, O.
AU - Gelmetti, C.
AU - Giannetti, A.
AU - Girolomoni, G.
AU - Vena, G. A.
AU - Cassano, N.
AU - Ayala, F.
PY - 2009
Y1 - 2009
N2 - The Italian Board on Urticaria has prepared a document focusing on the definition and classification of urticaria, taking into account the recent progress in identifying the causes, eliciting factors, and pathomechanisms of this disease. As urticaria has a profound impact on the quality of life, effective treatment is important. Therefore, specific treatment options for the management of urticaria are evaluated on the basis of the recent literature. Non-sedating H1 antihistamines are recommended as the first-line treatment as they have proven effective in several randomized double-blind controlled studies. Dosages higher than those recommended may be necessary in some cases. However, additional or alternative therapies may be required for different urticaria subtypes and in view of individual variations in the course of the disease and response to treatment. Immunosuppressive drugs such as corticosteroids are not recommended for long-term treatment due to unavoidable, severe adverse effects.
AB - The Italian Board on Urticaria has prepared a document focusing on the definition and classification of urticaria, taking into account the recent progress in identifying the causes, eliciting factors, and pathomechanisms of this disease. As urticaria has a profound impact on the quality of life, effective treatment is important. Therefore, specific treatment options for the management of urticaria are evaluated on the basis of the recent literature. Non-sedating H1 antihistamines are recommended as the first-line treatment as they have proven effective in several randomized double-blind controlled studies. Dosages higher than those recommended may be necessary in some cases. However, additional or alternative therapies may be required for different urticaria subtypes and in view of individual variations in the course of the disease and response to treatment. Immunosuppressive drugs such as corticosteroids are not recommended for long-term treatment due to unavoidable, severe adverse effects.
KW - Adrenal cortex hormones
KW - Immunosuppressive agents
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=68849090833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68849090833&partnerID=8YFLogxK
M3 - Article
C2 - 19528910
AN - SCOPUS:68849090833
VL - 144
SP - 297
EP - 311
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0392-0488
IS - 3
ER -